These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 35740503)

  • 21. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
    Barbie DA; Tamayo P; Boehm JS; Kim SY; Moody SE; Dunn IF; Schinzel AC; Sandy P; Meylan E; Scholl C; Fröhling S; Chan EM; Sos ML; Michel K; Mermel C; Silver SJ; Weir BA; Reiling JH; Sheng Q; Gupta PB; Wadlow RC; Le H; Hoersch S; Wittner BS; Ramaswamy S; Livingston DM; Sabatini DM; Meyerson M; Thomas RK; Lander ES; Mesirov JP; Root DE; Gilliland DG; Jacks T; Hahn WC
    Nature; 2009 Nov; 462(7269):108-12. PubMed ID: 19847166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.
    Saliani M; Jalal R; Ahmadian MR
    Cancer Biol Med; 2019 Aug; 16(3):435-461. PubMed ID: 31565476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutics Targeting Mutant KRAS.
    Thein KZ; Biter AB; Hong DS
    Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Breakthrough Brought about by Targeting KRAS
    Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defeat mutant KRAS with synthetic lethality.
    Pang X; Liu M
    Small GTPases; 2017 Oct; 8(4):212-219. PubMed ID: 27463838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
    Huang S; Ren X; Wang L; Zhang L; Wu X
    Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.
    Baldelli E; El Gazzah E; Moran JC; Hodge KA; Manojlovic Z; Bassiouni R; Carpten JD; Ludovini V; Baglivo S; Crinò L; Bianconi F; Dong T; Loffredo J; Petricoin EF; Pierobon M
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573384
    [No Abstract]   [Full Text] [Related]  

  • 28. KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy.
    Ambrogio C; Nadal E; Villanueva A; Gómez-López G; Cash TP; Barbacid M; Santamaría D
    ESMO Open; 2016; 1(5):e000076. PubMed ID: 27843638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic rewiring in mutant Kras lung cancer.
    Kerr EM; Martins CP
    FEBS J; 2018 Jan; 285(1):28-41. PubMed ID: 28570035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. More to the RAS Story: KRAS
    Lietman CD; Johnson ML; McCormick F; Lindsay CR
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.
    Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A
    Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS Oncogene Mutations in Colorectal Cancer Patients in a Nepalese Tertiary Care Hospital.
    Basnet BK; Gautam B; Ranabhat K; Paudel BD; Chapagain Acharya S; Bastola SR; Gyawali B
    J Nepal Health Res Counc; 2021 Dec; 19(3):504-507. PubMed ID: 35140422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS as a Therapeutic Target.
    McCormick F
    Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS Alleles: The Devil Is in the Detail.
    Haigis KM
    Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KRAS mutations in lung cancer.
    Karachaliou N; Mayo C; Costa C; Magrí I; Gimenez-Capitan A; Molina-Vila MA; Rosell R
    Clin Lung Cancer; 2013 May; 14(3):205-14. PubMed ID: 23122493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting KRAS in Non-Small Cell Lung Cancer.
    Corral de la Fuente E; Olmedo Garcia ME; Gomez Rueda A; Lage Y; Garrido P
    Front Oncol; 2021; 11():792635. PubMed ID: 35083149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.
    Thng DKH; Toh TB; Chow EK
    Trends Pharmacol Sci; 2021 Mar; 42(3):166-182. PubMed ID: 33422376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.